NEUWAY Pharma Appoints Healthcare Sector Veteran Dr Jacques Mallet to its Advisory Board
NEUWAY Pharma GmbH, « NEUWAY », a preclinical-stage biotechnology company specializing in the delivery of innovative biotherapeutic drugs through its proprietary EnPC® drug-delivery technology, announced today the appointment of Dr Jacques Mallet as an additional independent member of the Advisory Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220909005184/en/
Dr. Jacques Mallet (Photo: Business Wire)
Jacques Mallet, MD, previously served as SVP of Head of Portfolio Analytics/Corporate Strategy and Member of the Executive Leadership Team of Sanofi and is currently board member of several listed and private companies in the biotech and medtech sector.
"I’m delighted to join the Advisory Board to support NEUWAY in the development and growth of the company", said Dr Mallet. "I have been impressed by the great capabilities of the EnPC® drug-delivery technology and its therapeutic applications, which offers many advantages for drug developers and patients."
Dr Mallet brings more than 30 years of pharmaceutical industry experience within R&D, Pipeline Development and Corporate Strategy to NEUWAY, along with unique insights gained as a life-science venture capitalist in both in Europe and the United States. In addition to being responsible for investments at Auriga Partners, a French private-equity firm specializing in life sciences, Dr Mallet has also held executive positions in global consulting firms including Monitor Deloitte and Accenture.
Welcoming Dr Mallet, NEUWAY's Advisory Board Chairman and General Partner at Wellington Partners, Dr Rainer Strohmenger, said, "We are proud to have attracted such a distinguished expert to join the board of NEUWAY. Dr Mallet’s experience in clinical research and portfolio management, makes him an excellent fit for NEUWAY."
Dr Oliver Ernst, Chief Executive Officer of NEUWAY, added, "I am delighted to welcome Dr Mallet to our Board. With his extensive experience Dr Mallet will greatly support our corporate and product development efforts towards partnerships and the first clinical applications of our unique EnPC® drug-delivery technology.”
About NEUWAY Pharma
NEUWAY Pharma is developing an entirely novel class of biotherapeutics built around its proprietary Engineered Protein Capsules (EnPC®), which can cross the blood-brain barrier and deliver transformative neuropharmaceuticals for the treatment of disorders of the central nervous system (CNS).
Learn more at www.neuway-pharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005184/en/
Contact information
NEUWAY Pharma Contact:
Christine Kuhn
+49 228-522198-0
kuhn@neuway-pharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 11:51:00 EEST | Press release
Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon
NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 11:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui
Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA21.10.2025 11:00:00 EEST | Press release
Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support. “Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.” By hosting in Microsoft’s Netherlands Azure data centre, Impartner customers benefit from the assurance of GDPR-compliant data handling, best-in-class security and the spe
INNIO Secures Largest Order in Company History with VoltaGrid Delivering Power Generation for One of the World’s Largest Data Centers21.10.2025 10:01:00 EEST | Press release
INNIO Group today announced the largest order by power delivery in its history: a groundbreaking 2.3 GW power infrastructure project featuring 92 power packs, each delivering 25 MW of output. The initiative with VoltaGrid strengthens INNIO’s position as a key energy solutions provider for the rapidly expanding U.S. data center sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021503080/en/ INNIO Secures Largest Order in Company History (c) INNIO “This landmark order underscores the strength of INNIO’s technology and our ability to power the AI revolution with smart, high-performance energy solutions,” said Dr. Olaf Berlien, President and CEO of INNIO Group. “We are proud to partner with VoltaGrid in shaping the energy infrastructure of tomorrow.” “This is a major step toward building the energy infrastructure for the AI era,” added Nathan Ough, CEO of VoltaGrid. “Together with INNIO, we’re delivering a scalable solut
P.I. Works Celebrates 20 Years of Shaping the Telecom Industry21.10.2025 10:00:00 EEST | Press release
P.I. Works, the leading independent provider of AI-driven mobile network automation, optimization, and assurance solutions, proudly celebrates its 20th anniversary. This milestone marks two decades of driving telecom innovation and enabling mobile operators to deliver superior network performance, operational efficiency, and customer experience worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021105217/en/ P.I. Works Celebrates 20 Year Anniversary From Network Optimization to AI-Driven Automation Founded in 2005, as mobile data traffic surged with the rise of 3G, P.I. Works introduced intelligent solutions to help operators plan, manage, and optimize their networks more efficiently. Over the years, the company pioneered Self-Organizing Network (SON) capabilities, establishing the foundation for large-scale automation and giving operators the agility to manage increasingly complex networks. Leading Through the 5G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom